|
MechanismPRL-3 inhibitors |
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
一项针对实体瘤、评估PRL3-Zumab安全性和有效性的开放标签、多中心2期研究
[Translation] An open-label, multicenter phase 2 study evaluating the safety and efficacy of PRL3-Zumab in solid tumors
主要目的: 证明PRL3-Zumab在不可切除或转移性实体瘤患者中的疗效
[Translation] Primary objective: To demonstrate the efficacy of PRL3-Zumab in patients with unresectable or metastatic solid tumors
An Open Label, Multicenter, Safety and Efficacy Phase 2 Study of PRL3-Zumab in Solid Tumors
This is a multi-center, Phase 2, open-label, single dose level study of PRL3-zumab monotherapy in patients with unresectable or metastatic solid tumor.
An Open Label Phase II Study of the Efficacy and Tolerability of PRL3-ZUMAB and Predictive Biomarkers in Advanced Solid Tumours
This is a Phase II, open-label, single dose level study of PRL3-ZUMAB monotherapy in patients with advanced solid tumours that have failed standard therapy. Approximately 30 patients will be recruited with
10 gastric cancers and
10 hepatocellular carcinomas. Patients who have received at least 1 dose of PRL3-ZUMAB will be evaluable for toxicity and efficacy.
PRL3-ZUMAB will be given IV every 2 weeks for up to 12 infusions in the absence of unmanageable toxicities or disease progression. Patients who are benefitting from the treatment may continue on PRL3-ZUMAB beyond 12 infusions with the agreement of the study drug provider.
PRL3-ZUMAB at the RP2D in tumour types enriched for known PRL-3 expression for efficacy and tolerability will be evaluated. There will also be in depth molecular profiling of tissues in patients who have an objective response or prolonged disease stabilization to identify predictive/selection biomarkers as well as evaluation of the oncogenic signaling modulation and immunomodulation by PRL3-ZUMAB and its potential for future combination with other targeted therapies or immunotherapy.
100 Clinical Results associated with Intra-IMMUSG Pte Ltd
0 Patents (Medical) associated with Intra-IMMUSG Pte Ltd
100 Deals associated with Intra-IMMUSG Pte Ltd
100 Translational Medicine associated with Intra-IMMUSG Pte Ltd